Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy ... measures of physical ability, although ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

The delay - caused by FDA concerns over the quality of the data supporting eteplirsen - means rival DMD therapy developer Prosensa is now in pole position to bring its candidate drisapersen to market.

New Gene Therapy Approach Shows Promise for Duchenne Muscular Dystrophy July 24, 2024 — Researchers have made a significant breakthrough in developing a new gene therapy approach that restores ...

Allowing physical and occupational therapists to treat Medicare patients with less supervision could free up resources for ...

Belief Biomed Inc.’s gene therapy drug BBM-D101 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Duchenne muscular dystrophy (DMD).

A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...

Shelley DiCecco, PT, PhD, has been appointed interim chair of the Department of Physical Therapy at PCOM Georgia, where she ...

Discover the daily exercises and stretches recommended by a physical therapist to strengthen your body and enhance mobility.

Dynamic Strides is changing the way families can access physical, occupational and speech therapy in the Ozarks. The ...